Search research articles
Contact Us
Filters
Showing results (41-50 of 82) with videos related to
Page
of 9
Sort By:
Oncology Research and Treatment
|
December 4, 2022
Perspectives for Cancer Care and Research in Central and Eastern Europe
Christoph C Zielinski, Tanja Cufer, Bostjan Seruga, et al.
Journal of the National Cancer Institute
|
December 11, 2012
HER3 overexpression and survival in solid tumors: a meta-analysis
Alberto Ocana, Francisco Vera-Badillo, Bostjan Seruga, et al.
Plos One
|
March 28, 2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study
Amirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials
Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis
Saroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
JAMA Oncology
|
March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
Ariadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
Cancer Treatment Reviews
|
September 8, 2017
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis
Hadar Goldvaser, Ibrahim AlGorashi, Domen Ribnikar, et al.
Cancer Treatment Reviews
|
June 15, 2013
Fulvestrant for advanced breast cancer: a meta-analysis
Mustafa Al-Mubarak, Adrian G Sacher, Alberto Ocana, et al.
JAMA Oncology
|
February 4, 2021
Updating Reports of Phase 3 Clinical Trials for Cancer
Elena Elimova, Stephanie Moignard, Xuan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs
Saroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 82) with videos related to
Sort By:
Page
of 9
Oncology Research and Treatment
|
December 4, 2022
Perspectives for Cancer Care and Research in Central and Eastern Europe
Christoph C Zielinski, Tanja Cufer, Bostjan Seruga, et al.
Journal of the National Cancer Institute
|
December 11, 2012
HER3 overexpression and survival in solid tumors: a meta-analysis
Alberto Ocana, Francisco Vera-Badillo, Bostjan Seruga, et al.
Plos One
|
March 28, 2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study
Amirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials
Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis
Saroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
JAMA Oncology
|
March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
Ariadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
Cancer Treatment Reviews
|
September 8, 2017
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis
Hadar Goldvaser, Ibrahim AlGorashi, Domen Ribnikar, et al.
Cancer Treatment Reviews
|
June 15, 2013
Fulvestrant for advanced breast cancer: a meta-analysis
Mustafa Al-Mubarak, Adrian G Sacher, Alberto Ocana, et al.
JAMA Oncology
|
February 4, 2021
Updating Reports of Phase 3 Clinical Trials for Cancer
Elena Elimova, Stephanie Moignard, Xuan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs
Saroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Page
of 9